Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mirum Pharmaceuticals Q2 2024 GAAP EPS $(0.52) Misses $(0.47) Estimate, Sales $77.875M Beat $75.246M Estimate

Author: Benzinga Newsdesk | August 07, 2024 04:20pm
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.64 percent. The company reported quarterly sales of $77.875 million which beat the analyst consensus estimate of $75.246 million by 3.49 percent. This is a 107.68 percent increase over sales of $37.497 million the same period last year.

Posted In: MIRM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist